ALPN | Jotup

Alpine Immune Sciences Reports First Quarter 2024 Financial Results

Retrieved on:

星期四, 五月 9, 2024

Biotechnology, Pharmaceutical, Health, VRTX, ALPN, Investment, Research program, AbbVie, Research, Development, Alpine, Inflammation, Clinical trial, Vertex, Autoimmunity, Vertex Pharmaceuticals, Pharmaceutical industry

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024.

Key Points:

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024.
On April 10, 2024, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine announced that the companies had entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share in cash.
The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close in the second quarter of 2024.
Cash Position and Runway: As of March 31, 2024, Alpine's cash and investments totaled $362.4 million compared to $368.2 million as of December 31, 2023.

TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUSN

Retrieved on:

星期一, 四月 22, 2024

CVR, Vertex Pharmaceuticals, Sale, ALPN, AbbVie, Johnson & Johnson, Empire, AstraZeneca, Security (finance)

Under the terms of the agreement, ALPN shareholders are expected to receive $65.00 in cash per share they own.

Key Points:

Under the terms of the agreement, ALPN shareholders are expected to receive $65.00 in cash per share they own.
It is free and there is no cost or obligation to you.
Under the terms of the agreement, SWAV shareholders are expected to receive $335.00 in cash per share they own.
Before you hire a law firm, you should talk to a lawyer and ask:
Do you file class actions and go to Court?

Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy

Retrieved on:

星期三, 四月 10, 2024

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late breaking poster at the World Congress of Nephrology (WCN) April 13-16, 2024 in Buenos Aires, Argentina.

Key Points:

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late breaking poster at the World Congress of Nephrology (WCN) April 13-16, 2024 in Buenos Aires, Argentina.
RUBY-3 is a multiple ascending dose, multi-cohort, open label, phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, where povetacicept is administered subcutaneously (SC) once every four weeks.
As of March 01, 2024, 41 patients with IgAN had received povetacicept 80 or 240 mg subcutaneously every 4 weeks.
These data strongly support the inhibition of APRIL/BAFF pathways by povetacicept and its efficacy in the treatment of IgAN as well as the need for further clinical development.

ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders

Retrieved on:

星期四, 四月 11, 2024

Class Action Lawsuit, Professional Services, Legal, Sale, ALPN, Vertex, Advertising, Fraud, Vertex Pharmaceuticals

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alpine Immune Sciences, Inc. (NASDAQ: ALPN) to Vertex Pharmaceuticals Incorporated for $65.00 per share is fair to Alpine shareholders.

Key Points:

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alpine Immune Sciences, Inc. (NASDAQ: ALPN) to Vertex Pharmaceuticals Incorporated for $65.00 per share is fair to Alpine shareholders.
On behalf of Alpine shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024

Retrieved on:

星期一, 四月 1, 2024

Health, Hospitals, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, IgA nephropathy, Congress, Immunoglobulin A, Inflammation, Nephrology, Exhibition, Autoimmunity, ALPN, Pharmaceutical industry

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, has announced that the Company will present updated clinical data for povetacicept from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, in a late breaking poster presentation at the World Congress of Nephrology April 13-16, 2024 in Buenos Aires, Argentina.

Key Points:

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, has announced that the Company will present updated clinical data for povetacicept from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, in a late breaking poster presentation at the World Congress of Nephrology April 13-16, 2024 in Buenos Aires, Argentina.
Concurrently with the poster presentation, the Company will host an investor event on Monday, April 15th.
Poster Title: Updated Results from the RUBY-3 study of Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist in IgA Nephropathy
Presenter: James Tumlin, M.D., Professor of Medicine at Emory University School of Medicine, Founder and CEO of NephroNet Clinical Trials Consortium
Location: Exhibition Hall and Main Foyer, Buenos Aires Convention Center, Buenos Aires, Argentina

Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Retrieved on:

星期四, 三月 21, 2024

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for povetacicept (ALPN-303) at the SLEuro 14th European Lupus Meeting in Bruges, Belgium, March 19-22, 2024.

Key Points:

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for povetacicept (ALPN-303) at the SLEuro 14th European Lupus Meeting in Bruges, Belgium, March 19-22, 2024.
BAFF- and APRIL-related genes are increased in myeloid and B cells in systemic lupus erythematosus (SLE) patients compared to healthy adults.
Povetacicept significantly reduces multiple disease parameters in the NZB/W mouse model of lupus, more effectively than WT TACI-Ig or B cell depletion.
These findings are particularly intriguing considering that these organs are of particular relevance to our lead indications, systemic lupus erythematosus and IgA nephropathy.

Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Retrieved on:

星期三, 三月 20, 2024

Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Doctor of Philosophy, Conference, Autoimmunity, Inflammation, ALPN

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference.

Key Points:

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference.
Thursday, March 28th, Remy Durand, Ph.D., Chief Business Officer at Alpine, will participate in a fireside chat at 3:00 pm ET/12:00 pm PT and the Company will host investor meetings the same day.
Live webcasts of the fireside chats will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the event.

Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results

Retrieved on:

星期一, 三月 18, 2024

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported full year 2023 financial results and company highlights for the fourth quarter ended December 31, 2023.

Key Points:

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported full year 2023 financial results and company highlights for the fourth quarter ended December 31, 2023.
“2023 was a transformational year for Alpine, with initial IgA nephropathy (IgAN) data presented at the American Society of Nephrology Kidney Week 2023 suggesting a best-in-class profile for povetacicept, our next-generation dual BAFF/APRIL inhibitor.
In addition, povetacicept was well tolerated during subcutaneous administration, with no instances of IgG
Net Loss: Net loss for the year ended December 31, 2023, was $32.2 million compared to $57.8 million for the same period in 2022.

Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

星期四, 三月 7, 2024

Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ALPN, Webcast, Inflammation, Autoimmunity

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2023 financial results on Monday, March 18, 2024, after the close of market.

Key Points:

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2023 financial results on Monday, March 18, 2024, after the close of market.
The Company will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day.
The link to the webcast will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the live event.

Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences

Retrieved on:

星期一, 二月 26, 2024

Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Inflammation, Conference, ALPN, Doctor of Philosophy, IgA nephropathy, Autoimmunity

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences.

Key Points:

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences.
Monday, March 4th, Mitchell Gold, M.D., Executive Chairman and Chief Executive Officer will participate in an IgA Nephropathy corporate panel at 9:10 am ET/6:10 am PT during the TD Cowen 44th Annual Healthcare Conference in Boston, MA and the Company will host investor meetings the same day.
Tuesday, March 12th, Remy Durand, Ph.D., Chief Business Officer will participate in a fireside chat during the Leerink Partners Global Biopharma Conference in Miami, FL at 2:20 pm ET/11:20 am PT and the Company will host investor meetings the same day.
Live webcasts of the fireside chats will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the event.